Virax Biolabs Raises $1.5M in Direct Offering

TL;DR

Virax Biolabs just raised $1.5M via a direct offering at $1/share to boost working capital.

AI Summary

Virax Biolabs Group Ltd. announced a registered direct offering on August 21, 2024, to raise gross proceeds of approximately $1.5 million before deducting underwriting discounts and commissions. The offering involves the sale of 1,500,000 ordinary shares at a purchase price of $1.00 per share. The net proceeds are intended for general working capital and other general corporate purposes.

Why It Matters

This capital infusion provides Virax Biolabs with funds for working capital, potentially enabling further development and operational expansion of its diagnostic products.

Risk Assessment

Risk Level: medium — The company is raising capital through a direct offering, which can sometimes dilute existing shareholders and may indicate a need for funds.

Key Numbers

• $1.5M — Gross Proceeds (Raised from registered direct offering on August 21, 2024.)
• $1.00 — Price Per Share (The purchase price for the ordinary shares in the direct offering.)

Key Players & Entities

• Virax Biolabs Group Ltd. (company) — Registrant
• August 21, 2024 (date) — Date of registered direct offering announcement
• $1.5 million (dollar_amount) — Gross proceeds from the offering
• 1,500,000 (number) — Number of ordinary shares sold
• $1.00 (dollar_amount) — Purchase price per share

FAQ

Key Financial Figures

• $0.001 — (the “Shares”), par value $0.001 per share of the Company (the “O
• $4.50 — ;Ordinary Shares”) at a price of $4.50 per share. The Offering is expected to
• $5 m — roceeds to the Company of approximately $5 million, before deducting the placement a
• $5.625 — Offering and have an exercise price of $5.625 per share. In addition, the Company wil
• $35,000 — a non-accountable expense allowance of $35,000 and accountable legal expenses and othe
• $50,000 — tion with the Offering in the amount of $50,000. As previously disclosed on January 2
• $1,445,029 — g an aggregate offering amount of up to $1,445,029. On August 21, 2024, we notified Wainwr

Filing Documents

• 6-k_registered_direct_au.htm (6-K) — 40KB
• vrax-ex4_1.htm (EX-4.1) — 148KB
• vrax-ex5_1.htm (EX-5.1) — 62KB
• vrax-ex10_1.htm (EX-10.1) — 301KB
• vrax-ex99_1.htm (EX-99.1) — 16KB
• img35431341_0.jpg (GRAPHIC) — 2KB
• 0000950170-24-100027.txt ( ) — 571KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIRAX BIOLABS GROUP LIMITED Date: August 23, 2024 By: /s/ James Foster James Foster, Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR